01
01
Objectives
The main goal of MARION project is to develop novel imaging prognostic and response biomarkers that allow for a more precise care of mPC patients and that can be implemented in routine clinical practice in the public and private healthcare sector. Moreover, these biomarkers could also be used as intermediate endpoints for clinical trials, accelerating the development of new drugs for prostate cancer patients.
Complementary objectives
01
01
To evaluate PSMA expression by 18F -PSMA-PET as a response biomarker in prostate cancer.
02
02
To develop a novel non-invasive functional assays using dual whole-body MRI and 18F -PSMA-PET for prostate cancer monitoring .
03
03
To study the correlation between functional imaging and liquid-biopsy genomics features and build integrative models to use these data in clinical practice.
04
04
To derive quantitative measures of tumor heterogeneity using these assays, that can inform clinical evolution.
02
02
Innovations
Technologicals
The development of a new non-invasive imaging technique that can be delivered to patients in clinical practice.
Computational assessment of medical imaging data
Genomics and transcriptomics analysis of cancer
We believe that the aim of precision medicine requires the integration of multi-modality biomarkers that can unlock advances for patient care through an interdisciplinary approach to cancer research.
03
03
Partners
04
04
Results
The anticipated results of the project will have important applicability in the clinical practice and research fields. The follow-up of these patients using the new methodologies that the project test will allow for a more precise management of the disease in clinical practice, but also for more efficient evaluation of the antitumor activity of new agents in clinical trials PET-MRI combina en una única prueba las imágenes anatómicas y funcionales proporcionadas por la resonancia magnética (MRI) y los datos bioquímicos que ofrece la tomografía por emisión de positrones (PET).
Hence, we believe our approach can optimize both the routine clinical decision making and also the drug development path, impacting in the healthcare sector but also in the pharmaceutical industry from the R+D perspective.
.
.
.
.
04
04
Results
The anticipated results of the project will have important applicability in the clinical practice and research fields. The follow-up of these patients using the new methodologies that the project test will allow for a more precise management of the disease in clinical practice, but also for more efficient evaluation of the antitumor activity of new agents in clinical trials PET-MRI combina en una única prueba las imágenes anatómicas y funcionales proporcionadas por la resonancia magnética (MRI) y los datos bioquímicos que ofrece la tomografía por emisión de positrones (PET).
Hence, we believe our approach can optimize both the routine clinical decision making and also the drug development path, impacting in the healthcare sector but also in the pharmaceutical industry from the R+D perspective.
.
.
.
.
05
05
Financing
This Project is supported by the State Research Agency of the Ministry of Economy, Industry and Competitiveness, supported by EU FEDER funds.
Are you interested in getting to know us?
To get in touch or make any queries, fill out this form
